Introduction
NSCLC, non-small cell lung cancers, Cancer
NON-SMALL CELL LUNG CANCER, ADVERSE EFFECTS, NSCLC, CANCER
Edited by: Bin Duan, University of Nebraska Medical Center, United StatesReviewed by: Chunxia Su, Shanghai Pulmonary Hospital, China; Bixia Tang, Beijing Cancer Hospital, China†These authors contributed equally to this work and share first authorshipThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in ImmunologyThe treatment response to neoadjuvant immunochemotherapy varies among patients with potentially resectable non-small cell lung cancers (NSCLC) and may have severe immune-related adverse effects. We are currently unable to accurately predict therapeutic response. We aimed to develop a radiomics-based nomogram to predict a major pathological response (MPR) of potentially resectable NSCLC to neoadjuvant immunochemotherapy using pretreatment computed tomography (CT) images and clinical characteristics.